21 results
DEFM14A
INBX
Inhibrx Biosciences, Inc.
26 Apr 24
Proxy related to merger
4:06pm
’ compliance with applicable anti-bribery, anti-corruption, anti-money laundering laws and global trade control laws;
certain regulatory matters, including … with respect to “Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities” set forth in 56 Fed. Reg. 46191 (September 10, 1991
DEFA14A
INBX
Inhibrx Biosciences, Inc.
23 Jan 24
Additional proxy soliciting materials
6:38am
to provide a basis for the FDA to invoke its policy with respect to “Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities” set … (c).
“Anti-Corruption Laws” means the Foreign Corrupt Practices Act of 1977; the Anti-Kickback Act of 1986; the UK Bribery Act of 2010; Laws
8-K
EX-2.1
INBX
Inhibrx Biosciences, Inc.
23 Jan 24
Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B
6:35am
to provide a basis for the FDA to invoke its policy with respect to “Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities” set … (c).
“Anti-Corruption Laws” means the Foreign Corrupt Practices Act of 1977; the Anti-Kickback Act of 1986; the UK Bribery Act of 2010; Laws
8-K
EX-10.1
INBX
Inhibrx Biosciences, Inc.
29 Aug 23
Inhibrx Announces $200 Million Private Placement Financing
9:03am
or is in violation of any provision of the FCPA or any applicable non-U.S. anti-bribery statute or regulation; or (iv) made any unlawful bribe, rebate, payoff
S-3ASR
EX-1.2
3j5ozj2t8qk86icw
3 Sep 21
Automatic shelf registration
4:22pm
10-K
dcq3 ts9o5629b
12 Mar 21
Annual report
8:46am
10-Q
9makt3 vmms3716
13 Nov 20
Quarterly report
4:09pm
424B4
h7d7k0
19 Aug 20
Prospectus supplement with pricing info
5:21pm
DRS
v6ajdqzoqmfn xl
26 Jun 20
Draft registration statement
12:00am
S-1
9abt39
3 Jun 19
IPO registration
4:17pm
S-1
EX-10.23
9wn9 rrn1ros9l2o1l
3 Jun 19
IPO registration
4:17pm
S-1
EX-10.27
665ex6
3 Jun 19
IPO registration
4:17pm
DRS/A
EX-10.23
ve5nyp4epn2nu v6dj91
22 Feb 19
Draft registration statement (amended)
12:00am
DRS/A
on1yl311dpiia
22 Feb 19
Draft registration statement (amended)
12:00am